Topical treatments for chronic plaque psoriasis

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Mason, Anne R ^a   Mason, James ^b   Cork, Michael ^c   Dooley, Gordon ^d   Edwards, Gladys ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d Update Software Ltd   (United Kingdom)

^e Psoriasis Association   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; BUDESONIDE; CALCIPOTRIOL; CALCITRIOL; CICLOPIROX; CLOBETASOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; DESOXIMETASONE; DITHRANOL; FLUOCINONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HYDROCORTISONE; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; NOVASOME A; PARICALCITOL; PLACEBO; POLYMYXIN B; RO 24 0238; SALICYLIC ACID; TACALCITOL; TAZAROTENE; TRENITOIN; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VITAMIN D DERIVATIVE;

ADRENAL SUPPRESSION; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; FIBROMA; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; TACHYPHYLAXIS; UNSPECIFIED SIDE EFFECT;

EID: 70349111522     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005028.pub2     Document Type: Review

References (418)

1. Agrup G, Bjornberg A, Elmros T, Groth O, Hannuksela M, Lassus A, et al. Clinical Trial of a Potent Non-Halogenated Topical Steroid, Budesonide. Acta Dermato Venereologica 1981;61(2):180-182 [PUBMED: 6165205] (Pubitemid 11147577)
2. Austad J, Bjerke JR, Gjertsen BT, Helland S, Livden JK, Morken T, et al. Clobetasol Propionate Followed by Calcipotriol Is Superior to Calcipotriol Alone in Topical Treatment of Psoriasis. Journal of the European Academy of Dermatology & Venereology 1998;11(1):19-24. [PUBMED: 9731961] (Pubitemid 28383610)
3. Baiocchi R, Bertani E, Biggio P, Calandra P, De Marchi R, Franchi A, et al. Controlled Trial of the Efficacy and Safety of Calcipotriol Ointment Applied Once or Twice a Day in Psoriasis Vulgaris Studio [Controllato Per Emiparti Sull'efficacia E La Tollerabilita Di Calcipotriolo Unguento 1 Applicazione/Die Versus 2 Applicazioni/Die, Nella Psoriasi Volgare]. Giornale Italiano di Dermatologia e Venereologia 1997;132(2):139-147
4. Barker N, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. British Journal Of Dermatology 1999;141(2):274-278 [MEDLINE: 10468799] (Pubitemid 29397995)
5. * Barker N, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. British Journal Of Dermatology 1999;141(2):274-278 [PUBMED: 10468799]
6. Berth-Jones J. Maxacalcitol - a new, potent and safe vitamin D analogue for treatment of psoriasis. British Journal Of Dermatology 1999;141:992.
7. Bernhard J, Whitmore C, Guzzo C, Kantor I, Kalb RE, Ellis C, et al. Evaluation of Halobetasol Propionate Ointment in the Treatment of Plaque Psoriasis: Report on Two Double-Blind, Vehicle-Controlled Studies. Journal of the American Academy of Dermatology 1991;25(6 Pt 2):1170-1174 [PUBMED: 1757612]
8. Bernhard J, Whitmore C, Guzzo C, Kantor I, Kalb RE, Ellis C, et al. Evaluation of Halobetasol Propionate Ointment in the Treatment of Plaque Psoriasis: Report on Two Double-Blind, Vehicle-Controlled Studies. Journal of the American Academy of Dermatology 1991;25(6 Pt 2):1170-1174 [PUBMED: 1757612]
9. Berth Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, et al. A Multicentre, Parallel-Group Comparison of Calcipotriol Ointment and Short-Contact Dithranol Therapy in Chronic Plaque Psoriasis. British Journal Of Dermatology 1992;127(3):266-271 [PUBMED: 1390171]
10. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clinical & Experimental Dermatology 1993;18(6):504-506 [PUBMED: 8252786] (Pubitemid 23347631)
11. Bourke JF, Featherstone S, Iqbal SJ, Hutchinson PE. A Double-Blind Comparison of Topical Calcitriol (3 mcg/g) and Calcipotriol (50 mcg/g) in the Treatment of Chronic Plaque Psoriasis Vulgaris. British Journal Of Dermatology 1995;133(Suppl 45):17.
12. * Bourke JF, Iqbal SJ, Hutchinson PE. A Randomized Double-Blind Comparison of the Effects on Systemic Calcium Homeostasis of Topical Calcipotriol (3 Mu G/G) and Calcipotriol (50 U M/G) in the Treatment of Chronic Plaque Psoriasis Vulgaris. Acta Dermato Venereologica 1997;77(3):228-230 [PUBMED: 9188878]
13. * Bruce S, Epinette WW, Funicella T, Ison A, Jones EL, Loss RJ, et al. Comparative Study of Calcipotriene (Mc 903) Ointment and Fluocinonide Ointment in the Treatment of Psoriasis. Journal of the American Academy of Dermatology 1994;31(5 Pt 1):755-759 [PUBMED: 7929921]
14. Siskin SB. Efficacy and Safety of Calcipotriol Ointment Compared to Fluocinonide. 2nd International Symposium on Calcipotriol. Monaco, 1993.
15. Buckley DB. A Double-Blind Comparison of 0.1% Dithranol in a 17% Urea Base ("Psoradrate") and Base Alone in the Treatment of Active Chronic Psoriasis. Current Medical Research & Opinion 1978;5(6):489-494 [PUBMED: 350501 ]
16. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. Journal of Dermatological Treatment 2003;14(1):8-13. [PUBMED: 12745849] (Pubitemid 36417421)
17. * Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; Vol.206, issue 2:153-156 [MEDLINE: 12592084]
18. Cannavo SP, Guarneri F, Vaccaro M, Borgia FAD, Institute of Dermatology University of Messina Italy. Treatment of psoriatic nails with topical cyclosporin. 11th Congress of the European Academy of Dermatology and Venereology. 2002:P27-89.
19. Cheesbrough MJ. Treatment of psoriasis with 30% Dead Sea salt lotion. Journal Of Dermatological Treatment 1992;3(4):201-203. [EMBASE: 1993020259]
20. Christensen OB, Mork NJ, Ashton R, Daniel F, Anehus S. Comparison of a treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. Journal Of Dermatological Treatment 1999;10(4):261-265. [EMBASE: 2000044219]
21. Crosti C, Finzi AF, Mian E, Scarpa C. Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropionate + salicylic acid. International Journal Of Dermatology 1997;36(7):537-539 [PUBMED: 9268756] (Pubitemid 27355970)
22. Cunliffe WJ, Berth Jones J, Claudy A, Fairiss GM, Goldin D, Gratton D, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. Journal of the American Academy of Dermatology 1992;26(5 Pt 1):736-743 [MEDLINE: 1583173]
23. DeSimone C, Guerriero C, Morini P, Venier A. Treatment of Psoriasis with Topical Calcipotriol [Il Calcipotriol Nella Terapia Locale Della Psoriasi]. Giornale Italiano di Dermatologia e Venereologia 1993;128(10):Ic-Ciii.
24. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Dermato Venereologica 2002;82(2):131-135 [PUBMED: 12125943 ] (Pubitemid 34596689)
25. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, et al. Efficacy and Safety of Calcipotriol (Mc 903) Ointment in Psoriasis Vulgaris. A Randomized, Double-Blind, Right/Left Comparative, Vehicle-Controlled Study. Journal of the American Academy of Dermatology 1992;27(6 Pt 1):983-988 [PUBMED: 1479106]
26. Durakovic C, Malabanan A, Holick MF. Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study. British Journal Of Dermatology 2001;144(3):500-506 [PUBMED: 11260006] (Pubitemid 32232003)
27. Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1 alpha, 25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. British Journal of Dermatology 2004;151(1):190-195 [PUBMED: 15270890] (Pubitemid 39061298)
28. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdulla SA. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. International Journal of Clinical Pharmacology Research 2000;20(3-4):65-68 [PUBMED: 11314240]
29. Elie R, Durocher LP, Kavalec EC. Effect of Salicylic Acid on the Activity of Betamethasone-17,21-Dipropionate in the Treatment of Erythematous Squamous Dermatoses. Journal of International Medical Research 1983;11(2):108-112 [PUBMED: 6852357 ]
30. Ellis CN, Horwitz SN, Menter A. Amcinonide Lotion 0.1% in the Treatment of Patients with Psoriasis of the Scalp. Current Therapeutic Research - Clinical and Experimental 1988;44(2):315-324. [EMBASE: 1989232557] (Pubitemid 19002095)
31. Escobar SO, Achenbach R, Iannantuono R, Torem V. Topical fish oil in psoriasis - a controlled and blind study. Clinical & Experimental Dermatology 1992;17(3):159-162 [PUBMED: 1451289 ]
32. Farkas B, Dobozy A. Comparison of Tacalcitol with Dithranol. 3rd European Hermal Symposium. Hamburg, 1995.
33. * Farkas B, Dobozy A, Horvath A, Hunyadi J, Schneider I. Comparison of tacalcitol ointment with short-contact dithranol therapy in the treatment of psoriasis vulgaris: a randomized multicentre, open prospective study on efficacy and safety. Journal Of Dermatological Treatment 1999;10:93-99 [EMBASE: 1999259658]
34. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal Of Dermatology 1999;38(8):628-632 [PUBMED: 10487457 ]
35. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal Of Dermatology 2000;39(7):535-538 [PUBMED: 10940121]
36. Geilen CC, Mrowietz U. Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. Journal of the American Academy of Dermatology 2000;42(5 Pt 1):837-840 [PUBMED: 10775867 ] (Pubitemid 30252895)
37. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. Journal of Cutaneous Medicine & Surgery 2003;7(3):185-192 [PUBMED: 12704534 ]
38. Grattan CEH, Hallam F, Whitefield M. A New Aqueous Dithranol Gel for Psoriasis: Comparison with Placebo and Calcipotriol Ointment. Journal Of Dermatological Treatment 1997;8(1):11-15 [EMBASE: 1997109958] (Pubitemid 27156778)
39. Grattan CEH, Hallam F, Whitefield M. A New Aqueous Dithranol Gel for Psoriasis: Comparison with Placebo and Calcipotriol Ointment. Journal Of Dermatological Treatment 1997;8(1):11-15 [EMBASE: 1997109958] (Pubitemid 27156778)
40. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative Effects of Calcipotriol (Mc903) Solution and Placebo (Vehicle of Mc903) in the Treatment of Psoriasis of the Scalp. British Journal Of Dermatology 1994;130(4):483-487 [PUBMED: 8186114 ] (Pubitemid 24204668)
41. Greenspan A, Herndon JJ, Baker MD, Cheney T. Controlled Evaluation of 0.05% Desonide Lotion and Desonide Cream in Psoriasis. Current Therapeutic Research - Clinical and Experimental 1993;53(6):614-620. [EMBASE: 1993261649] (Pubitemid 23261635)
42. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. Journal of the American Academy of Dermatology 2004;51(5):731-738 [PUBMED: 15523351] (Pubitemid 39516887)
43. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clinical Therapeutics 2000;22(10):1225-1238 [PUBMED: 11110233]
44. * Guenther L, Van De Kerkhof PCM, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. British Journal Of Dermatology 2002;147(2):316-323 [PUBMED: 12174105]
45. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. British Journal of Dermatology 2004;151(3):663-668 [PUBMED: 15377355]
46. van de Kerkhof PCM. A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life in patients with psoriasis vulgaris. 11th Congress of the European Academy of Dermatology and Venereology. 2002:P27-2.
47. * Guenther L, Van De Kerkhof PCM, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. British Journal Of Dermatology 2002;147(2):316-323 [PUBMED: 12174105]
48. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. British Journal of Dermatology 2004;151(3):663-668 [MEDLINE: 15377355]
49. van de Kerkhof PCM. A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life in patients with psoriasis vulgaris. 11th Congress of the European Academy of Dermatology and Venereology. 2002:P27-2.
50. Han GW, Yu BT, Li H, Zhu XJ, Wang BX, Li GM, et al. A randomized controlled multicenter clinical trial on tazarotene gel versus calcipotriol ointment in the treatment of plaque psoriasis vulgaris. The Chinese Journal of Clinical Pharmacology 2001;17(6):419-422
51. Harrington CI, Goldin D, Lovell CR, Van De Kerkhof P, Nieboer C, Austad J, et al. Comparative Effects of Two Different Calcipotriol (Mc 903) Cream Formulations Versus Placebo in Psoriasis Vulgaris. A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Multi-Centre Study 1. Journal of the European Academy of Dermatology & Venereology 1996;6(2):152-158 [EMBASE: 1996096735] (Pubitemid 126424906)
52. Henneicke-von Zepelin HH, Mrowietz U, Farber L, Bruck-Borchers K, Schober C, Huber J, et al. Highly purified omega-3-polyunsaturated fatty acids for topical treatment of psoriasis. Results of a double-blind, placebo-controlled multicentre study. British Journal Of Dermatology 1993;129(6):713-717 [PUBMED: 8286257] (Pubitemid 24003560)
53. Highton A, Quell J, Breneman D, Cullen S, Goffe B, Griffiths C, et al. Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. Journal of the American Academy of Dermatology 1995;32(1):67-72. [PUBMED: 7822519]
54. Holick MF, Chimeh FN, Ray S. Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial. British Journal of Dermatology 2003;149(2):370-376 [PUBMED: 12932245]
55. Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3μg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000;201(2):139-145 [PUBMED: 11053917] (Pubitemid 30823551)
56. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology: JDD 2004;3(4):367-373 [PUBMED: 15303780]
57. Jekler J, Swanbeck G. One-Minute Dithranol Therapy in Psoriasis: A Placebo-Controlled Paired Comparative Study. Acta Dermato Venereologica 1992;72(6):449-450 [PUBMED: 1362841] (Pubitemid 23028351)
58. Jin HZ, Wang JB, He ZX, Xie Y. A Randomized, Placebo, Controlled, Double Blind Trial Study on IL-8 Monoclonal Antibody Cream in the Treatment of Psoriasis Vulgaris. The Chinese Journal of Clinical Pharmacology 2001;17(1):36-40.
59. Jorizzo Jl, Magee K, Stewart DM, Lebwohl MG, Rajagopalan R, Brown JJ. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal- axis safety and four-week clinical efficacy results in plaque-type psoriasis. Cutis 1997;60(1):55-60. [PUBMED: 9252738] (Pubitemid 127470437)
60. Kang S, Yi S, Griffiths CEM, Fancher L, Hamilton TA, Choi JH. Calcipotriene-Induced Improvement in Psoriasis Is Associated with Reduced Interleukin-8 and Increased Interleukin-10 Levels within Lesions. British Journal Of Dermatology 1998;138(1):77-83. [PUBMED: 9536226] (Pubitemid 28077941)
61. Kanzler MH, Gorsulowsky DC. Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. British Journal Of Dermatology 1993;129(3):310-314 [PUBMED: 8286230]
62. Katz HI, Hien NT, Prawer S, Scot JC, Grivna EM. Betamethasone Dipropionate in Optimized Vehicle. Intermittent Pulse Dosing for Extended Maintenance Treatment of Psoriasis. Archives of Dermatology 1987;123(10):1308- 1311 [PUBMED: 3662562] (Pubitemid 17152291)
63. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183(4):269-274 [PUBMED: 1809589]
64. Katz HI, Gross E, Buxman M, Prawer SE, Schwartzel EH, Gibson JR. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. Journal of the American Academy of Dermatology 1991;25(6 Pt 2):1175-1178 [PUBMED: 1757613]
65. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet(TM)) Is an Effective Once-Daily Treatment for Psoriasis vulgaris. Dermatology 2002;205(4):389-393 [PUBMED: 12444337] (Pubitemid 35356768)
66. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet(TM)) Is an Effective Once-Daily Treatment for Psoriasis vulgaris. Dermatology 2002;205(4):389-393 [PUBMED: 12444337] (Pubitemid 35356768)
67. Kim JY, You YH, Kim TY, Kim CW. Comparative Study of Calcipotriol and Desoxymethasone Ointments in the Treatment of Psoriasis Vulgaris. The Clinical Effect and Immunohistochemical Change. Korean Journal of Dermatology 1994;32(6):1054-1063 [EMBASE: 1995058111]
68. Carder KR. A randomized double blind parallel group dose-ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. Abstract 844. Journal of Investigative Dermatology 1996;106(4):946.
69. * Kiss I, McCreary HL, Siskin SB, Epinette WW. A Randomized, Double- Blind, Parallel Group, Dose-Ranging Comparison of the Efficacy and Safety of Calcipotriene Solution in the Treatment of Scalp Psoriasis. American Academy of Dermatology, 54th annual Meeting. 1996; Vol.Poster abstract - P301.
70. Klaber MR, Hutchinson PE, Pedvis-Leftick A, Kragballe K, Reunala TL, Van de Kerkhof PC, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal Of Dermatology 1994;131(5):678-683 [PUBMED: 7999600] (Pubitemid 24344055)
71. Klaber MR, McKinnon C. Calcipotriol (DovonexR) scalp solution in the treatment of scalp psoriasis: Comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (CapasalR) shampoo, and long-term experience. Journal Of Dermatological Treatment 2000;11(1):21-28 [EMBASE: 2000114933] (Pubitemid 30171146)
72. Kragballe K, Beck HI, Søgaard H. Improvement of Psoriasis by a Topical Vitamin D3 Analogue (Mc 903) in a Double-Blind Study. British Journal Of Dermatology 1988;119(2):223-230 [EMBASE: 1988203615] (Pubitemid 18203615)
73. Kragballe K, Gjertsen BT, DeHoop D, Karlsmark T, van de Kerkhof PC, Larko O, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337(8735):193-196 [PUBMED: 1670840]
74. Glade CP, Van Erp PE, Van De Kerkhof PC. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study. British Journal Of Dermatology 1996;135(3):379-384 [PUBMED: 8949429]
75. * Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, et al. Calcipotriol Cream with or without Concurrent Topical Corticosteroid in Psoriasis: Tolerability and Efficacy. British Journal Of Dermatology 1998;139(4):649-654 [MEDLINE: 9892908]
76. van de Kerkhof PC. Calcipotriol cream and concurrent corticosteroids in psoriasis. Journal of the European Academy of Dermatology & Venereology 1995; Vol.5, issue Suppl 1:S184.
77. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. British Journal of Dermatology 2004;150(6):1167-1173 [PUBMED: 15214905] (Pubitemid 38932288)
78. Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Archives of Dermatology 1998;134(1):57-60. [PUBMED: 9449910] (Pubitemid 28087114)
79. Köse O. Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal Of Dermatological Treatment 1997;8:287. [EMBASE: 1998022654] (Pubitemid 28033807)
80. Landi G. Efficacy and safety of calcipotriol ointment compared to clobetasol ointment in psoriasis vulgaris. 3rd congress of the European Academy of Dermatology and Venereology. Copenhagen, Denmark, 1993:199.
81. * Landi G, Pierleoni M, Polverelli M, Fioravanti F. Calcipotriol, a New Topical Product in the Therapy of Psoriasis: Controlled Study Versus Clobetasol [Il Calcipotriol, Nuovo Topico Nella Terapia Della Psoriasi: Studio Controllato Versus Clobetasol]. Giornale Italiano di Dermatologia e Venereologia 1993;128(9):89-93. [EMBASE: 1993360641]
82. Lane AT, Wachs GN, Weston WL. Once-Daily Treatment of Psoriasis with Topical Glucocorticosteroid Ointments. Journal of the American Academy of Dermatology 1983;8(4):523-525 [PUBMED: 6853785]
83. Langner A, Verjans H, Stapor V, Mol M, Fraczykowska M. 1 Alpha ,25-Dihydroxyvitamin D-3 (Calcitriol) Ointment in Psoriasis. Journal Of Dermatological Treatment 1992;3(4):177-180. [EMBASE: 1993020253] (Pubitemid 23020253)
84. Langner A, Verjans H, Stapor V, Mol M, Fraczykowska M. Topical Calcitriol in the Treatment of Chronic Plaque Psoriasis: A Double-Blind Study. British Journal Of Dermatology 1993;128(5):566-571 [PUBMED: 8504051] (Pubitemid 23155957)
85. Langner A, Stapor W, Ambroziak M. Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. British Journal Of Dermatology 2001;58:11-16. [PUBMED: 11501507] (Pubitemid 32374823)
86. Langner A, Stapor W, Ambroziak M. Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. British Journal Of Dermatology 2001;58:11-16. [PUBMED: 11501507] (Pubitemid 32374823)
87. Lassus A, Forsstrom S. A double-blind study comparing oleum horwathiensis with placebo in the treatment of psoriasis. Journal of International Medical Research 1991;19(2):137-146 [PUBMED: 1864450]
88. Lebwohl M, Scher RK, Washenik K, Krueger G, Menter A, Koo J, et al. A randomized, double-blind placebo-controlled study of the safety and efficacy of clobetasol propionate 0.05% foam in the treatment of non-scalp psoriasis.. Skin Pharmacology & Applied Skin Physiology 2001;14:168.
89. * Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. International Journal Of Dermatology 2002;41(5):269-274. [PUBMED: 12100701]
90. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. Journal of the American Academy of Dermatology 2004;51(5):723-730 [PUBMED: 15523350] (Pubitemid 39516886)
91. LepawMI. Double-Blind Comparison of Halcinonide Solution and Placebo Control in Treatment of Psoriasis of the Scalp. Cutis 1978;21(4):571-573 [PUBMED: 346315]
92. Lister RK, Woodrow Sl, Hughes JH, Cerio R, Norris PG, Griffiths CEM, et al. Can dithranol have a lasting effect and be more acceptable to patients? Micanol Cream - a trial of 171 patients with psoriasis. British Journal of Dermatology 1997;137(Suppl 50):17.
93. Medansky RS, Brody NI, Kanof NB, Russo GJ, Peets EA. Clinical Investigations of Mometasone Furoate - a Novel Nonfluorinated, Topical Corticosteroid. Seminars In Dermatology 1987;6(2):94-100. [EMBASE: 1988051740]
94. Medansky RS, Greenspan A, Kraus SJ, Todd Plott R. The Comparative Efficacy of Diflorasone Diacetate Ointment 0.05% (Psorcon®) vs Calcipotriene Ointment (Dovonex®) in the Treatment of Psoriasis. Journal of Geriatric Dermatology 1996;4(1):20-24.
95. Molin L, Cutler TP, Helander I, Nyfors B. Calcipotriol cream and betamethasone valerate cream of equal efficacy in psoriasis. Journal of the European Academy of Dermatology & Venereology 1995;5(Suppl 1):S92.
96. Molin L, Cutler TP, Helander I, Nyfors B. Comparative Efficacy of Calcipotriol Cream and Betamethasone Valerate Cream in the Treatment of Psoriasis. Journal of Investigative Dermatology. Symposium Proceedings 1996;1(1):110.
97. * Molin L, Cutler TP, Helander I, Nyfors B, Downes N. Comparative Efficacy of Calcipotriol (Mc903) Cream and Betamethasone 17-Valerate Cream in the Treatment of Chronic Plaque Psoriasis. A Randomized, Double-Blind, Parallel GroupMulticentre Study. Calcipotriol Study Group. British Journal Of Dermatology 1997;136(1):89-93. [PUBMED: 9039301]
98. Monastirli A, Zografakis CH, Braun H, Pasmatzi E, Georgiou S, Sakkis TH, et al. Calcipotriol vs. Anthralin in the treatment of chronic plaque psoriasis. H+G Zeitschrift Fur Hautkrankheiten. 2000;75(11):626-629 [EMBASE: 2000428558]
99. Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P. Treatment of Psoriasis Vulgaris with Topical Calcipotriol Has No Short-Term Effect on Calciumor BoneMetabolism. A Randomized, Double-Blind, Placebo-Controlled Study. Acta Dermato Venereologica 1993;73(4):300-304 [PUBMED: 7904106] (Pubitemid 23282979)
100. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology 1991;24(3):443-447 [PUBMED: 2061442]
101. Olsen EA. Efficacy and Safety of Fluticasone Propionate 0.005% Ointment in the Treatment of Psoriasis. Cutis 1996;57(2 Suppl): 57-61. [PUBMED: 8646872]
102. Olsen EA. Efficacy and Safety of Fluticasone Propionate 0.005% Ointment in the Treatment of Psoriasis. Cutis 1996;2 Suppl:57-61. [PUBMED: 8646872]
103. Oranje AP, Marcoux DS, A, Prendiville J, Krafchik B, Toole J, Rosenthal D, et al. Topical calcipotriol in childhood psoriasis. Journal of the American Academy of Dermatology 1997;36(2 Pt 1):203-208 [PUBMED: 9039169]
104. Ormerod AD, Dwyer CM, Weller R, Cox DH, Price R. A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. Journal of the American Academy of Dermatology 1997;37(1):51-57 [PUBMED: 9216523 ] (Pubitemid 27287693)
105. Ormerod AD, Copeland P, Shah SA. Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. British Journal Of Dermatology 2000;142(5):985-990 [PUBMED: 10809860] (Pubitemid 30304613)
106. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. British Journal of Dermatology 2005;152(4):758-764 [PUBMED: 15840110 ] (Pubitemid 40571311)
107. Ortonne JP, Bazex J, Binet O, Bombart M, Brun P, Carreau O, et al. Psoriasis: New Therapeutic Modality by Calcipotriol and Betamethasone Dipropionate. Nouvelles Dermatologiques 1994;13(10):746-751 [EMBASE: 1995010294]
108. Nicolas JF. Calcitriol vs calcipotriol in psoriasis of sensitive areas Abstract. 20th World Congress of Dermatology. Paris, 2002:SA1048.
109. * Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. British Journal of Dermatology 2003;148(2):326-333 [PUBMED: 12588387]
110. * Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: A randomised, double-blind trial. Dermatology (Basel) 2004;209(4):308-313 [PUBMED: 15539894]
111. Ortonne JP, Traulsen J, Kaufmann R, Lecha M, Goodfield M. Calcipotriol/betamethasone dipropionate ointment once daily versus tacalcitol once daily in psoriasis vulgaris. Abstract P27-49 The 12th Congress of the European Academy of Dermatology and Venereology. Barcelona, Spain 15-18th October 2003. Journal of the European Academy of Dermatology & Venereology. 2003; Vol.17, issue Suppl 3:374.
112. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. Journal of the American Academy of Dermatology 2003;48(1):48-54. [PUBMED: 12522370] (Pubitemid 36091533)
113. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. Journal of the American Academy of Dermatology 2003;48(1):48-54. [PUBMED: 12522370] (Pubitemid 36091533)
114. Pariser DM, Pariser RJ, Breneman D, Lebwohl M, Kalb R, Moore J, Moss H, Parker C, Fiedler V. Calcipotriene ointment applied once a day for psoriasis: A double- blind, multicenter, placebo-controlled study. Archives of Dermatology 1996;132(12):1527. [PUBMED: 8961897] (Pubitemid 26424568)
115. Pauporte M, Maibach H, Lowe N, Pugliese M, Friedman DJ, Mendelsohn H, et al. Fluocinolone acetonide topical oil for scalp psoriasis. Journal of Dermatological Treatment 2004;15(6):360-364 [PUBMED: 15764047] (Pubitemid 39657846)
116. Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, et al. Efficacy and Safety of Topical Calcitriol (1,25-Dihydroxyvitamin D3) for the Treatment of Psoriasis. British Journal Of Dermatology 1996;134(2):238-246 [PUBMED: 8746336] (Pubitemid 126735526)
117. Pinheiro N. Comparative Effects of Calcipotriol Ointment (50 Micrograms/G) and 5% Coal Tar/2% Allantoin/0.5% Hydrocortisone Creamin Treating Plaque Psoriasis. British Journal of Clinical Practice 1997;51(1):16-19 [PUBMED: 9158266] (Pubitemid 27129544)
118. Reygagne P, Mrowietz U, Decroix J, Van der Spek W, Olmos Acebes L, Figueiredo A, et al. Four-week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. 11th Congress of the European Academy of Dermatology and Venereology. 2002:P27-36.
119. Ruzicka T, Kallinschnigg G, Lorenz B, Schroder G. Clinical Efficacy of a Monotherapy with Calcipotriol-Ointment Compared to Combination Therapy with Calcipotriol Ointment and Betamethasone Valerate Ointment in Psoriasis Vulgaris. Journal of Investigative Dermatology 1996;1(1):107.
120. * Ruzicka T, Lorenz B. Comparison of Calcipotriol Monotherapy and a Combination of Calcipotriol and Betamethasone Valerate after 2 Weeks' Treatment with Calcipotriol in the Topical Therapy of Psoriasis Vulgaris: A Multicentre, Double-Blind, Randomized Study. British Journal Of Dermatology 1998;138(2):254-258 [PUBMED: 9602870]
121. Salmhofer W, Maier H, Soyer HP, Honigsmann H, Hodl S. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Dermato Venereologica. Supplementum 2000;211:5-8. [PUBMED: 11234559] (Pubitemid 32156242)
122. Sanchez Regana M, Iglesias Sancho M, Umbert Millet P. Treatment of plague-type psoriasis with topical propylthiouracil. Actas Dermo Sifiliograficas 2001;92(4):174-176. [EMBASE: 2001206374] (Pubitemid 32523433)
123. Santoianni P, Di Iorio S, Giannetti A, Manfredi G, Rebora A, Landi G, et al. Short-term clinical efficacy of the association betamethasone 17-valerate 21-acetate + tretinoine + salicylic acid in outpatients affected with disseminated keratotic plaque psoriasis: A double blinded placebo-controlled multicentric randomized clinical trial. Giornale Italiano di Dermatologia e Venereologia 2001;136(1):77-83. [EMBASE: 2001160666] (Pubitemid 32385615)
124. Scarpa C. Calcipotriol: Clinical Trial Versus Betamethasone Dipropionate + Salicylic Acid. Acta Dermato Venereologica, Supplementum 1994;186:47. [PUBMED: 8073835] (Pubitemid 24208149)
125. * Scarpa C. Tacalcitol Ointment Is an Efficacious and Well Tolerated Treatment for Psoriasis. Journal of the European Academy of Dermatology & Venereology 1996;6(2):142-146 [EMBASE: 1996096733]
126. Scarpa C, Kokelj F, Plozzer C, Lavaroni G. Efficacy and Tolerability of Tacalcitol Ointment on Psoriatic Skin: Study in 63 Patients. Journal of Investigative Dermatology. Symposium Proceedings 1996;1(1):110.
127. Scarpa C, Kokelj F, Plozzer C, Lavaroni G, Torsello P. Efficacy and Tolerability of Tacalcitol Administered Once Daily in the Treatment of Psoriasis Vulgaris (Double-Blind, Randomized, Placebo Controlled Italian Multicenter Study). Giornale Italiano di Dermatologia e Venereologia 1997;132(5):335-338 [EMBASE: 1997363332] (Pubitemid 27501726)
128. Scher R. Tazarotene 0.1% gel in the treatment of nail psoriasis. Abstract. 20th World Congress of Dermatology. 2002:P0791.
129. * Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001;68(5):355-358 [PUBMED: 11766122]
130. Scher RK, Stiller M, Zhu YI. Treating fingernail psoriasis with tazarotene 0.1% gel: A vehicle-controlled study. Skin Pharmacology & Applied Skin Physiology 2001;14(3):170.
131. Sears HW, Bailer JW, Yeadon A. A Double-Blind, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Hydrocortisone Buteprate 0.1% Cream in the Treatment of Psoriasis. Advances In Therapy 1997;14(3):140-149 [EMBASE: 1997223749]
132. Seidenari S, Magni R, Giannetti A. Assessment of the Activity of Tacalcitol on Psoriatic Plaques by Means of Colorimetry and High-Frequency Ultrasound: A Double-Blind Intrasubject Half-Side Right-Left Comparison with Betamethasone Valerate and Placebo. Skin Pharmacology 1997;10(1):40-47 [EMBASE: 1997139265] (Pubitemid 27196910)
133. Seidenari S, Magni R, Giannetti A. Assessment of the Activity of Tacalcitol on Psoriatic Plaques by Means of Colorimetry and High-Frequency Ultrasound: A Double-Blind Intrasubject Half-Side Right-Left Comparison with Betamethasone Valerate and Placebo. Skin Pharmacology 1997;10(1):40-47 [EMBASE: 1997139265] (Pubitemid 27196910)
134. Shuttleworth D, Galloway DB, Boorman GC, A.E. D. A double-blind, placebo-controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal Of Dermatological Treatment 1998;9(3):163-167 [EMBASE: 1998346163] (Pubitemid 28469986)
135. Staberg B, Roed-Petersen J, Menne T. Efficacy of Topical Treatment in Psoriasis with Mc903, a New Vitamin D Analogue. Acta Dermato Venereologica 1989;69(2):147-150 [PUBMED: 2564233] (Pubitemid 19057355)
136. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U. Betamethasone valerate foam for treatment of nonscalp psoriasis. Journal of Cutaneous Medicine & Surgery 2001;5(4):303-307 [PUBMED: 11907840] (Pubitemid 32843785)
137. Hoffmann M, Memmel U, Altmeyer P, Stuecker M. Topical treatment of chronic-stationary plaque psoriasis with vitamin B12. (Ger.). Zeitschrift Fur Hautkrankheiten 2001;Suppl. 1(76):S12.
138. * Stuecker M, Memmel U, Hoffmann M, Hartung J, Altmeyer P. Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology 2001;203(2):141-147 [PUBMED: 11586013]
139. Stutz JA, N. EC, Kang S. Failure of topical polymyxin B to improve mild plaque psoriasis [letter]. Archives of Dermatology 1996;132(2):231. [PUBMED: 8629837] (Pubitemid 26058518)
140. Sudilovsky A, Muir JG, Bocobo FC. A Comparison of Single and Multiple Applications of Halcinonide Cream. International Journal Of Dermatology 1981;20(9):609-613 [PUBMED: 7030988] (Pubitemid 12216476)
141. Sutton L, Swinehart JM, Cato A, Kaplan AS. A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. International Journal Of Dermatology 2001;40(7):464-467 [MEDLINE: 11679005] (Pubitemid 32982303)
142. Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Tropical Medicine & International Health 1996;1(4):505-509 [PUBMED: 8765459] (Pubitemid 26264419)
143. Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. Journal of Cutaneous Medicine & Surgery 2001;5(4):299-302. [PUBMED: 11907839]
144. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. British Journal Of Dermatology 1994;131(5):673-677 [PUBMED: 7999599]
145. Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, et al. Calcipotriol Ointment in Nail Psoriasis: A Controlled Double-Blind Comparison with Betamethasone Dipropionate and Salicylic Acid. British Journal Of Dermatology 1998;139(4):655-659 [MEDLINE: 9892909] (Pubitemid 28474312)
146. van de Kerkhof PCM, van Bokhoven M, Zultak M, Czarnetzki BM. A Double-Blind Study of Topical 1 Alpha,25-Dihydroxyvitamin D3 in Psoriasis. British Journal Of Dermatology 1989;120(5):661-664 [PUBMED: 2667612] (Pubitemid 19143299)
147. van de Kerkhof PCM, Werfel T, Haustein UF, Luger T, Czarnetzki BM, Niemann R, et al. Tacalcitol Ointment in the Treatment of Psoriasis Vulgaris: A Multicentre, Placebo- Controlled, Double- Blind Study on Efficacy and Safety. British Journal Of Dermatology 1996;135(5):758-765 [PUBMED: 8977677] (Pubitemid 26375894)
148. van de Kerkhof PCM, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, et al. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002;204(3):214-221 [PUBMED: 12037450] (Pubitemid 34628311)
149. van der Vleuten CJM, de Jong EMGJ, Rulo EHFC, Gerritsen MJP, Van de Kerkhof PCM. In-Patient Treatment with Calcipotriol Versus Dithranol in Refractory Psoriasis. European Journal of Dermatology 1995;5(8):676-679 [EMBASE: 1996010645]
150. Vanderploeg DE. Betamethasone Dipropionate Ointment in the Treatment of Psoriasis and Atopic Dermatitis: A Double-Blind Study. Southern Medical Journal 1976;69(7):862-863 [PUBMED: 781848]
151. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. British Journal Of Dermatology 1997;137(4):581-586 [PUBMED: 9390335] (Pubitemid 27469510)
152. Vladimirov VV, Tcherjomukchina IG, Kurjanova ON, Menshikova LV, Mazina NM. Efficacy of calcipotriol ointment compared to betamethasone 17-valerate ointment in the treatment of psoriasis. Skin Therapy Update. Crete, Greece, 1994:219.
153. Volden G, Bjornberg A, Tegner E, Pedersen NB, Arles UB, Agren S, et al. Short-Contact Treatment at Home with Micanol. Acta Dermato Venereologica. Supplementum 1992;172:20-22 [PUBMED: 1585757]
154. Wall AR, Poyner TF. Psoriasis; the Burden of Disease Before, During and After Treatment with Dovonex Ointment or Dithrocream. British Journal Of Dermatology 1997;137(Suppl 50):55.
155. * Wall ARJ, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. British Journal Of Dermatology 1998;139(6):1005-1011 [PUBMED: 9990363]
156. Weinstein GD. Safety, Efficacy and Duration of Therapeutic Effect of Tazarotene Used in the Treatment of Plaque Psoriasis. British Journal Of Dermatology 1996;135(Suppl 49):32-36 [PUBMED: 9035703]
157. * Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a newretinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Journal of the American Academy of Dermatology 1997;37(1):85-92. [PUBMED: 9216528]
158. Weinstein GD. Tazarotene creamin the treatment of plaque psoriasis Abstract. 20th World Congress of Dermatology. 2002:P2043.
159. * Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Twomulticenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. Journal of the American Academy of Dermatology 2003;48(5):760-767 [PUBMED: 12734506]
160. Wolska H, Laws S, Schulz-Kiesow M, Grossman R, Jablonska S, Stadlers R, et al. Clinical evaluation of a PAF-antagonist in psoriasis vulgaris. Journal Of Dermatological Treatment 1995;6(1):43-45 [EMBASE: 1995125049]
161. Wortzel MH. A new corticosteroid for moderate/severe dermatoses. Clinical medicine 1975;82(3):23-26
162. Wortzel WH. A new corticosteroid for moderate/severe dermatoses. Clinical medicine 1975;82(3):23-26
163. Wozel G. Treatment of chronic-stationary psoriasis with fluocinolone acetonide and calcipotriol. (Ger.). Zeitschrift Fur Hautkrankheiten 2001;76(7-8):482.
164. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Archives of Dermatology 1998;134(9):1101-1102 [PUBMED: 9762021] (Pubitemid 28432323)
165. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Archives of Dermatology 1998;134(9):1101-1102 [PUBMED: 9762021] (Pubitemid 28432323)
166. Ambroziak M, Stapor W, Langner A, Kwiek B. Clinical evaluation of the scalp psoriasis treatment with clobetasol propionate 0.05% lotion. [Polish]. Przeglad Dermatologiczny 2002;89(3):237-240 (Pubitemid 35256600)
167. Baadsgaard O, Traulsen J, Roed Petersen J, Jakobsen HB. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. Journal Of Dermatological Treatment 1995;6(3):145-150
168. Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. Journal Of Dermatological Treatment 1999;10:201-204 (Pubitemid 29438082)
169. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. British Journal of Dermatology 2003;149(1):207-209 (Pubitemid 36966543)
170. Callen J. Comparison of Safety and Efficacy of Fluticasone Propionate Cream, 0.05%, and Betamethasone Valerate Cream, 0.1%, in the Treatment of Moderate-to-Severe Psoriasis. Cutis 1996;57(2 Suppl):45-50. (Pubitemid 126733617)
171. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Archives of Dermatology 2005;141(1):43-46 (Pubitemid 40144438)
172. De Jong EM, Menke HE, Van Praag MC, Van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999;199(4):313-318
173. Elias AN, Dangaran K, Barr RJ, Rohan MK, Goodman MM. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis. Journal of the American Academy of Dermatology 1994;31(3 Pt 1):455-458 (Pubitemid 24273316)
174. Jansen C, Lammintausta K, Bullingham RES, Forsstrom S. A Clinical Trial of Lonapalene Fluocinolone Acetonide and Vehicle in Psoriasis. Journal of Investigative Dermatology. Meeting Abstract 1986;86(4):483.
175. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (Mc 903). Archives of Dermatology 1989;125(12):1647-1652 (Pubitemid 20060609)
176. Kragballe K, Dam TN, Hansen ER, Baadsgaard O, Gronhoj Larsen F, Sondergaard J, et al. Efficacy and Safety of the 20-Epi-Vitamin D3 Analogue Kh 1060 in the Topical Therapy of Psoriasis: Results of a Dose-Ranging Study. Acta Dermato Venereologica 1994;74(5):398-402. (Pubitemid 24305862)
177. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene Ointment and Halobetasol Ointment in the Long-Term Treatment of Psoriasis: Effects on the Duration of Improvement. Journal of the American Academy of Dermatology 1998;39(3):447-450 (Pubitemid 28417383)
178. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. International Journal Of Dermatology 2001;40(1):64-66 [MEDLINE: 11277960] (Pubitemid 32201237)
179. Levin C, Fiorentino DF, Vosganian G, Chon S, Kimball AB. The safety of topical cyclosporin A conjugate (CGC1072) in the treatment of mild to moderate psoriasis. Abstract 1201 International Investigative Dermatology. The 4th Joint Meeting of the ESDR, Japanese SID & SID, 30th April-4th May 2003, Florida, USA. Journal of Investigative Dermatology 2003;121(1):201.
180. Meyrat R, Muller I. Daivonex registered trade mark ointment twice a day versus Daivonex registered trade mark cream in the morning and Daivonex registered trade mark ointment in the evening. Ars Medici 1996;86(20):1218-1220 (Pubitemid 27037255)
181. Reygagne P, Diaconu J, Près H, Ernst TM, Meyer KG, S.A.D A. Efficacy and safety comparison of clobetasol propionate shampoo, gel and vehicle in scalp psoriasis. 11th Congress of the European Academy of Dermatology and Venereology. 2002:P27-9.
182. Ruzicka T, Trompke C. [Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion]. Hautarzt 2004;55(2):165-170
183. Sander P, Stucker M, Hermes N, Hoffmann K, Altmeyer P. Mometasone and calcipotriol optimise the initial therapeutic effect of dithranol on chronic plaque psoriasis [Mometason Und Calcipotriol Optimieren Den Therapeutischen Initialeffekt Von Dithranol Auf Die Chronisch Stationare Psoriasis (CSP)]. Hautarzt 1998;49(4):291-294
184. Sefton J, Loder JS, Kyriakopoulos AA. Clinical Evaluation of Hydrocortisone Valerate 0.2% Ointment. Clinical Therapeutics 1984;6(3):282-293 (Pubitemid 14129398)
185. Sharma V, Kaur I, Kumar B. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. International Journal of Dermatology 2003;42(10):834-838 (Pubitemid 37304055)
186. Syed TA, Qureshi ZA. Management of psoriasis of the scalp with methotrexate (0.25%) in an aerosolized spray gel. A placebo-controlled, double-blind study. Skin Pharmacology & Applied Skin Physiology 2001;14(3):167.
187. Tokura Y. Effectiveness of Combination between Diflucortolone Valerate and Vitamin D3 Analogue in the Treatment of Psoriasis Vulgaris. [Japanese]. Nishinihon Journal of Dermatology 2004;66(2):188-191. (Pubitemid 38508777)
188. Tzaneva S, Honigsmann H, Tanew A. Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis. British Journal of Dermatology 2003;149(2):350-353 (Pubitemid 37107339)
189. van de Kerkhof PCM, Kuypers A. A randomised, double blind, left right study to compare hydrocortisone 17-butyrate 0.1% emulsion with vehicle in the treatment of patients suffering from psoriasis vulgaris. 6th International Skin Symposium. Brussels, 1996; Vol.Poster P16.
190. Bernstein S, Donsky H, GulliverW, Hamilton D, Nobel S, Norman R. Treatment of mild to moderate psoriasis with Relieva, a Mahonia aquifolium extract - a double-blind, placebo-controlled study. American Journal of Therapeutics 2006; Vol.13, issue 2:121-126 (Pubitemid 43755121)
191. Beutner K, Chakrabarty A. An intra-individual safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Abstract P2858. American Academy of Dermatology 64th Annual Meeting March 3-7, 2006.
192. Journal of the American Academy of Dermatology 2006; Vol.54, issue 3 Suppl:AB212.
193. Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. Journal of Drugs in Dermatology 2006; Vol.5, issue 4:357-360
194. Brown AC, Koett J, Johnson DW, Semaskvich NM, Holck P, Lally D, et al. Effectiveness of kukui nut oil as a topical treatment for psoriasis. International Journal of Dermatology 2005; Vol.44, issue 8:684-687 (Pubitemid 41179614)
195. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; Vol.217, issue 2:107-113
196. de Korte J, van der Valk PG, Sprangers MA, Damstra RJ, Kunkeler AC, Lijnen RL, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. British Journal of Dermatology 2008; Vol.158, issue 2:375-381
197. Friedrich M, Vollhardt K, Zahlten R, Sterry W, Wolff G. Demonstration of antipsoriatic efficacy of a new topical formulation of the small molecule selectin antagonist bimosiamose Abstract P016 European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology & Venereology 2004; Vol.18, issue 6:779.
198. Gold LS. Correlation between amount of drug used versus efficacy of calcipotriene/betamethasone in severe psoriasis during a 52-week study. Abstract P2873. American Academy of Dermatology 64th Annual Meeting March 3-7, 2006. Journal of the American Academy of Dermatology 2006; Vol.54, issue 3 Suppl:AB216.
199. Gottschalk RW, Johnson LA. Calcitriol 3 micrograms/g versus calcipotriol 50 micrograms/g for plaque psoriasis: treatment, maintenance and cost Abstract P2720. American Academy of Dermatology 65th Annual Meeting February 2-6, 2007. Journal of the American Academy of Dermatology 2007; Vol.56, issue 2:AB179.
200. Helfrich YR, Kang S, Hamilton TA, Voorhees JJ. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study. British Journal of Dermatology 2007; Vol.157, issue 2:369-374 (Pubitemid 47083870)
201. Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006; Vol.78, issue 5:348-354
202. Jemec GBE, Burden D, Poulin Y, Ortonne JP. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle Abstract P2733. American Academy of Dermatology 65th Annual Meeting February 2-6, 2007. Journal of the American Academy of Dermatology 2007; Vol.56, issue 2:AB182.
203. Jemec GBE, Ganslandt C, Ortonne J-P, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology 2008; Vol.59, issue 3:455-463
204. Ji S, Chen X, Wang B, Jin H, Zhao G, Wang Y, Chen Z, Liu X, Gu J, Guo Z, Zhu X. Calcitriol ointment versus calcipotriol ointment in the treatment of psoriasis: a single-blind, randomized, multicenter trial (Chinese). Zhonghua Pifuke Zazhi 2008; Vol.41, issue 3:153-156. [: BIOSIS]
205. Jorizzo J. Efficacy with calcipotriene and betamethasone dipropionate ointment in patients with moderate and severe psoriasis Abstract P2780. American Academy of Dermatology 65th Annual Meeting February 2-6, 2007. Journal of the American Academy of Dermatology 2007; Vol.56, issue 2:AB194.
206. Kaur I, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) vs tazarotene (0.05%, 0.1%) in stable plaque psoriasis. Abstract P015 European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology & Venereology 2004; Vol.18, issue 6:779.
207. Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foamin the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. Journal of the American Academy of Dermatology 2006; Vol.55, issue 4:637-641 (Pubitemid 44436646)
208. Kragballe K, Bibby A. Long-term efficacy of a calcipotriene/betamethasone dipropionate two compound product in Psoriasis vulgaris. Abstract P2891. American Academy of Dermatology 64th Annual Meeting March 3-7, 2006. Journal of the American Academy of Dermatology 2006; Vol.54, issue 3 Suppl:AB220.
209. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. British Journal of Dermatology 2006; Vol.154, issue 6:1155-1160 (Pubitemid 43727399)
210. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; Vol.213, issue 4:319-326 (Pubitemid 44837020)
211. Kreuter A, Sommer A, Hyun J, Brautigam M, Brockmeyer NH, Altmeyer P, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Archives of Dermatology 2006; Vol.142, issue 9:1138-1143 (Pubitemid 44414397)
212. Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. Journal of Drugs in Dermatology: JDD 2007; Vol.6, issue 4:428-435
213. Lee J, Youn J, Kim N, Kim K, Kim T, Choi J, et al. A randomized investigator-blinded comparative study of calcitriol twice a day vs. diflucortolone valerate morning plus calcitriol evening application in the treatment of mild to moderate psoriasis. Journal of the European Academy of Dermatology and Venereology 2007; Vol.21, issue Suppl. 1:19.
214. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. British Journal of Dermatology 2007; Vol.157, issue 5:1005-1012
215. Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. Journal of Dermatological Treatment 2005; Vol.16, issue 3:158-164 (Pubitemid 41364775)
216. Luger T, Kidson P, Cambazard F, Larsen FG. A 1-year, randomized, double-blind safety study of long-term treatment of a new gel formulation containing calcipotriene plus betamethasone dipropionate in scalp psoriasis. Journal of the American Academy of Dermatology 2008; Vol.58, issue 2:AB134.
217. Luger TA, Cambazard F, Larsen FG, Bourcier M, Gupta G, Clonier F, et al. A Study of the Safety and Efficacy of Calcipotriol and Betamethasone Dipropionate Scalp Formulation in the Long-Term Management of Scalp Psoriasis. Dermatology 2008; Vol.217, issue 4:321-328
218. Maier H. Prospective, randomized controlled double-blind study on the efficacy and safety of a series of herbal skin-care products for stable chronic plaque psoriasis. Abstract P061 European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology & Venereology 2004; Vol.18, issue 6:794.
219. Menter A, Colon L, Johnson L, Gottschalk R. Results from a randomized study comparing clobetasol propionate 0.05% spray to calcipotriene 0.005%, betamethasone dipropionate 0.064% ointment for the treatment of plaque psoriasis. Journal of the American Academy of Dermatology 2008; Vol.58, issue 2:AB124.
220. Ortonne J-P, van de Kerkhof PCM, Prinz JC, Bieber T, Lahfa M, Rubins A, et al. 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. Acta Dermato-Venereologica 2006; Vol.86, issue 1:29-33. (Pubitemid 46939785)
221. Powers J, Balin AK, Kempers S, Glinert RJ, Fleming T, Graeber M. Assessment of the efficacy and safety of calcitriol 3ugg-1 ointment in the treatment of chronic plaque psoriasis. Abstract P-40 The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK. British Journal of Dermatology 2005; Vol.153, issue Suppl 1:32.
222. Powers J. Assessment of the Efficacy and Safety of Calcitriol 3mcg/g Ointment in the Treatment of Chronic Plaque Psoriasis. 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia 28th September -1st October, 2005 2005:367.
223. Reygagne P, Mrowietz U, Decroix J, De Waard-Van Der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05%and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment 2005; Vol.16, issue 1:31-36 (Pubitemid 40283322)
224. Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. Journal of Dermatological Treatment 2007; Vol.18, issue 6:361-365
225. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. Journal of Dermatological Treatment 2007; Vol.18, issue 1:40-45 (Pubitemid 46410643)
226. Van De Kerkhof PCM. Once daily vs. twice daily applications of topical treatments in psoriasis [15]. British Journal of Dermatology 2005; Vol.153, issue 6:1245.
227. van de Kerkhof PC, van der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. British Journal of Dermatology 2006; Vol.155, issue 4:800-807 (Pubitemid 44352562)
228. van de Kerkhof P, Anstey A, Barnes L, Bolduc C. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle Abstract P2734. American Academy of Dermatology 65th Annual Meeting February 2-6, 2007. Journal of the American Academy of Dermatology 2007; Vol.56, issue 2:AB182.
229. White S, Vender R, Thaci D, Haverkamp C, Naeyaert J-M, Foster R, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. American Journal of Clinical Dermatology 2006; Vol.7, issue 3:177-184 (Pubitemid 43845342)
230. Xuejun Z, BaoxiW, Guang Z, Jun G, Zhiqiang C, Briantais P, et al. A comparison of the efficacy and safety of twice daily applications of calcitriol 3 lg/g ointment versus calcipotriol 50 mcg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. Abstract P0647. The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12-15th October 2005. Journal of the European Academy of Dermatology & Venereology 2005; Vol.19, issue Suppl 2:172.
231. Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects withmild tomoderate chronic plaque-type psoriasis. Journal of the European Academy of Dermatology & Venereology 2007; Vol.21, issue 4:466-472 (Pubitemid 46454898)
232. Topical Vitamin B12 in Chronic Plaque Psoriasis. Ongoing study January 2001.
233. Study to Compare U0267 Foam Against Vehicle Foam in Subjects With Plaque-Type Psoriasis. Ongoing study April 2008.
234. Efficacy and safety of calcipotriene / Betamethasone Gel / Ointment in Psoriasis. Ongoing study Octrober 2006.
235. Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis. Ongoing study September 2006.
236. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris. Ongoing study December 2005.
237. Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds. Ongoing study February 2008.
238. Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis. Ongoing study August 2006.
239. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris. Ongoing study April 2008.
240. Treatment of Psoriasis With Parathyroid Hormone. Ongoing study January 2000.
241. Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis. Ongoing study November 2004.
242. LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis. Ongoing study January 2007.
243. Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis. Ongoing study May 2006.
244. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis. Ongoing study February 2005.
245. A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis. Ongoing study October 2007.
246. Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis. Ongoing study September 2006.
247. Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis. Ongoing study September 2004.
248. Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis. Ongoing study January 2008.
249. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis. Ongoing study December 2004.
250. Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris. Ongoing study April 2005.
251. Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test. Ongoing study September 2004.
252. Randomised, observer-blinded, vehicle-controlled trial on the efficacy and safety of a topical indigo naturalise ointment treatment for recalcitrant psoriasis vulgaris. Ongoing study 01/05/2004.
253. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris. Ongoing study October 2005.
254. Afifi T, de Gannes G, Huang C, Zhou Y. Topical therapies for psoriasis: evidence-based review. Canadian Family Physician 2005; Vol.51:519-525 (Pubitemid 40528840)
255. Angus JE, Andriolo RB, Bigby M, Goodman SN, Jobling R, Williams HC. Biologics for chronic plaque psoriasis (Protocol). Cochrane Database of Systematic Reviews 2006, issue 4:Art. No.: CD006138. DOI: 10.1002/14651858. CD006138.pub2.
256. Ashcroft DM, LiWan Po A, Williams HC, Griffiths CE. Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol in the treatment of mild to moderate plaque psoriasis. Pharmacoeconomics 2000;18(5):469-476 (Pubitemid 30825705)
257. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; Vol.320, issue 7240:963-967 (Pubitemid 30192863)
258. Aste N. Tacalcitol ointment in the treatment of psoriasis. Giornale Italiano di Dermatologia e Venereologia 2004;139(1):81-84
259. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health & Quality of Life Outcomes 2004;2(1):12. (Pubitemid 39112018)
260. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: Results of a pilot study. Journal of the American Academy of Dermatology 2003;49(4):651-654 (Pubitemid 37210278)
261. Barisic-Drusko V, Dobric I, Pasic A, Paljan D, Jukic Z, Basta-Juzbasic A, et al. Frequency of psoriatic arthritis in general population and among the psoriatics in department of dermatology. Acta Dermato-Venereologica. Supplementum. 1994;186:107-108 (Pubitemid 24208171)
262. Barker JN. The pathophysiology of psoriasis. Lancet 1991;338(8761):227- 230
263. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. European Journal of Dermatology 2000;10(3):199-204. (Pubitemid 30186558)
264. Berth Jones. Immediate and long term effects of topical calcipotriol on calcium homeostatis during treatment of psoriasis. Abstract. British Journal of Dermatology. 1992; Vol.127, issue Suppl 40:17.
265. Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE. Urine Calcium Excretion During Treatment of Psoriasis with Topical Calcipotriol. British Journal Of Dermatology 1993;129(4):411-414 (Pubitemid 23308245)
266. Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Human Molecular Genetics 1998;7(10):1537-1545 (Pubitemid 28464030)
267. Bleiker TO, Bourke JF, Mumford R, Hutchinson PE. Long-Term Outcome of Severe Chronic Plaque Psoriasis Following Treatment with High-Dose Topical Calcipotriol. British Journal Of Dermatology 1998;139(2):285-286 (Pubitemid 28389403)
268. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary No. 54. London: BMJ Books, 2007.
269. Bonifati C, Carducci M, Mussi A, D'Auria L, Ameglio F. Recognition and treatment of psoriasis: special considerations in elderly patients. Drugs & Aging 1998;12(3):177-190 (Pubitemid 28130094)
270. Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. British Journal of Dermatology 2002;146(2):342.
271. Bos JD, Spuls PI. Topical treatments in psoriasis: today and tomorrow. Clinics in Dermatology. Elsevier Inc 2008; Vol.26, issue 5:432-437
272. Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. British Journal of Dermatology 1993;129(1):74-76 (Pubitemid 23211052)
273. Bourke JF, Berth-Jones J, Mumford R, Iqbal SJ, Hutchinson PE. High dose topical calcipotriol consistently reduces serum-parathyroid hormone levels. Clinical Endocrinology 1994;41(3):295-297 (Pubitemid 24278322)
274. Brandrup F, Hauge M, Henningsen K, Eriksen B. Psoriasis in an unselected series of twins. Archives of Dermatology 1978;114(6):874-878
275. Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. British Journal of Dermatology 2007; Vol.157, issue 1:213. (Pubitemid 46934285)
276. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB, Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatology Online Journal. 2003; Vol.9, issue 1:2.
277. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Ebling FJG editor(s). Textbook of Dermatology. Oxford: Blackwell Science, 1992:1391-1458
278. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. Journal of the American Academy of Dermatology 2006; Vol.54, issue 4 Suppl 1:S171-81. (Pubitemid 43238300)
279. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. British Journal of Dermatology 2004;151(4):895-897 (Pubitemid 39482127)
280. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. Journal of the American Academy of Dermatology 2004;51(2):212-216
281. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. Interventions for guttate psoriasis. Cochrane Database of Systematic Reviews 2000; Vol.2. [MEDLINE: Review]
282. Chalmers RJG, Hollis S, Leonardi-Bee J, Griffiths CEM, Marsland AM. Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2006, issue 1:CD001433.
283. Chu T. Better patient compliance in psoriasis. Practitioner 2000;244(1608):238-242
284. Corbett MF. The response of psoriasis to betamethasone valerate and clobetasol propionate: a 6-month controlled study. British Journal Of Dermatology 1976;12:89-93.
285. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. British Journal of Dermatology 2003;149(3):582-589 (Pubitemid 37281592)
286. Cullen SI. Long-Term Effectiveness and Safety of Topical Calcipotriene for Psoriasis. Calcipotriene Study Group. Southern Medical Journal 1996;89(11):1053-1056
287. de Jong EM. The course of psoriasis. Clinics in Dermatology 1997;15(5):687-692
288. De Tiedra A, Mercadal J, Lozano R. Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study. Pharmacoeconomics 1997;12(2 Pt 1):193-208. (Pubitemid 27323227)
289. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Archives of Dermatology 1975;111(5):581-583
290. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Archives of Dermatology 1974;109(2):207-211
291. Feldman SR, Fleischer AB, Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. Journal of the American Academy of Dermatology 1997;37(4):564-569
292. Feldman SR, Sahu S, Fleischer AB, Jr, Dezii CM. Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective cohort study of the cost of psoriasis treatment with topical corticosteroids versus topical calcipotriene. Journal of Cutaneous Medicine & Surgery 2000;4(3):121-125 (Pubitemid 30666541)
293. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. Journal of the American Academy of Dermatology 2007;57(1):81-83 (Pubitemid 46908856)
294. Ferrandiz C, Bielsa I, Ribera M, Fuente MJ, Carrascosa JM. Reinforcement Therapy in Patients with Psoriasis Treated with Calcipotriol Cream Terapia De Refuerzo En Pacientes Con Psoriasis Tratada Con Calcipotriol. Actas Dermo Sifiliograficas 1998;89(11):626-630.
295. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clinical & Experimental Dermatology 1994;19(3):210-216
296. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. British Journal of Dermatology 1995;132(2):236-244
297. Finlay AY. Coping with psoriasis. BMJ 1995;310(6995):1673.
298. Finlay AY. Psoriasis from the patient's point of view. Archives of Dermatology 2001;137(3):352-353
299. Finlay AY. Current severe psoriasis and the rule of tens. British Journal of Dermatology 2005;152(5):861-867
300. Floden C, Woodbridge P, Samman P, Kurwa AR. Comparison of the Response of Psoriasis, over a 6-Month Period, to Clobetasol Propionate and Fluocinolone Acetonide Ointments. Current Medical Research & Opinion 1975;3(6):375-381
301. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in Dermatology 2008; Vol.26, issue 4:380-386
302. Fortune DG, Richards HL, Kirby B, McElhone K, Markham T, Rogers S, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Archives of Dermatology 2003;139(6):752-756 (Pubitemid 36705942)
303. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. Journal of the European Academy of Dermatology & Venereology 2005;19 Suppl 3:2-6.
304. Franssen ME, van der Wilt GJ, de Jong PC, Bos RP, Arnold WP. A retrospective study of the teratogenicity of dermatological coal tar products. Acta Dermato-Venereologica 1999;79(5):390-391
305. Fredriksson T, Lassus A, Bleeker J. Treatment of psoriasis and atopic dermatitis with halcinonide cream applied once and three times daily. British Journal of Dermatology 1980;102(5):575-577 (Pubitemid 10117046)
306. Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg g(-1) ointment. British Journal Of Dermatology 2001;144(Suppl 58):17-19 (Pubitemid 32374824)
307. Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clinics in Dermatology 2007; Vol.25, issue 6:574-580
308. Goeckerman WH. Treatment of psoriasis. A. M. A. archives of dermatology and syphilology 1931;24:446-450
309. Gokdemir G, Ari S, Köslü A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. Journal of the European Academy of Dermatology and Venereology 2008;22(3):330-335 (Pubitemid 351247423)
310. Griffiths CEM. The immunological basis of psoriasis. Journal of the European Academy of Dermatology & Venereology 2003;17(s2):1-5.
311. Griffiths CEM. Psoriasis: future research needs and goals for the twenty-first century. Dermatologic Clinics 2004; Vol.22, issue 4:493-499
312. Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. British Journal of Dermatology 2007; Vol.156, issue 2:258-262 (Pubitemid 46095952)
313. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; Vol.370, issue 9583:263-271
314. Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis; cutaneous medicine for the practitioner 1998;61(6):339-342
315. Gupta G, Bhattacharya S. Psoriasis: maximizing topical treatment concordance. British Journal of Hospital Medicine 2007;68(5):263-266 (Pubitemid 46814835)
316. Guzzo C, Lazarus G, Goffe BS, Katz HI, Lowe NJ, Pincus SH. Topical Calcipotriene Has No Short-Term Effect on Calcium and Bone Metabolism of Patients with Psoriasis. Journal of the American Academy of Dermatology 1996;34(3):429-433 (Pubitemid 26083819)
317. Harries M, Ball DFJ, Mrowietz U, Chalmers R, Griffiths CEM. Fumaric acid esters for psoriasis (Protocol). Cochrane Database of Systematic Reviews 2005, issue 4:Art. No.: CD005499. DOI: 10.1002/14651858.CD005499.
318. Harries M, Butterworth A, Griffiths CEM, Chalmers R. Methotrexate for psoriasis (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 2..
319. Cochrane Database of Systematic Reviews 2005, issue 2:Art. No.: CD005204. DOI: 10.1002/14651858.CD005204.
320. Harrington CI. Cost-Effectiveness Analysis of Calcipotriol Ointment and 'Short-Contact' Dithranol in Treating Mild-to-Moderate Psoriasis. British Journal Of Medical Economics 1995;8(1):27-32.
321. Hellgren L. Psoriasis. The prevalence in sex, age and occupational groups in total populations in Sweden: morphology, inheritance and association with other skin and rheumatic diseases. Stockholm: Almqvist &Wiksell, 1967.
322. Heng MC, Heng Hl, Allen SG. Basement Membrane Changes in Psoriatic Patients on Long-Term Topical Corticosteroid Therapy. Clinical & Experimental Dermatology 1990;15(2):83-90.
323. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology 2006;54(1):1-15; quiz 16-18
324. Henseler T, Koch F, Westphal E, Nair RP, Vorhees JJ, Elder JT, et al. Presence of HLA-DR7 in type-I-psoriasis. Clinical Research 1992;40:A457.
325. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2008.
326. Holick MF, Chen ML, Kong XF, Sanan DK. Clinical uses for calciotropic hormones 1, 25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology: a new perspective. Journal of Investigative Dermatology. Symposium Proceedings 1996;1(1):1-9.
327. Ingram JT. The approach to psoriasis. BMJ 1953;ii:591-594
328. Janjua A, Chalmers R, Zheng A, Xiang Y, Harries M, Griffiths CEM, et al. Oral retinoids for psoriasis (Protocol). Cochrane Database of Systematic Reviews 2006, issue 3:Art. No.: CD006139. DOI: 10.1002/14651858.CD006139.
329. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australasian Journal of Dermatology 2002;43(4):255-261 (Pubitemid 35365414)
330. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-46 (Pubitemid 32682008)
331. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. Journal of Investigative Dermatology 2003; Vol.120, issue 3: 456-464 (Pubitemid 36298433)
332. Katz HI, Hien NT, Prawer SE, Mastbaum LI, Mooney JJ, Samson CR. Superpotent Topical Steroid Treatment of Psoriasis Vulgaris - Clinical Efficacy and Adrenal Function. Journal of the American Academy of Dermatology 1987;16(4):804-811
333. Katz HI, Prawer SE, Mooney JJ, Samson CR. Preatrophy: Covert Sign of Thinned Skin. Journal of the American Academy of Dermatology 1989;20(5 Pt 1):731-735
334. Kragballe K, Beck HI, Søgaard H. Improvement of psoriasis by a topical vitamin D3 analogue (Mc 903) in a double-blind study. British Journal of Dermatology 1988;119(2):223-230. (Pubitemid 18203615)
335. Kragballe K, Fogh K, Sogaard H. Long-Term Efficacy and Tolerability of Topical Calcipotriol in Psoriasis. Results of an Open Study. Acta Dermato Venereologica 1991;71(6):475-478
336. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. Journal of the American Academy of Dermatology 1984;11(5 Pt 2):937-947
337. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. Journal of the American Academy of Dermatology 2000;43(2 Pt 1):281-285 (Pubitemid 30626007)
338. Lambert J. Economic Analyses of the Treatment of Psoriasis. European Journal of Dermatology 1996;6(8):543-547
339. Lambert J. Cost-Effectiveness of Treatments in Psoriasis. Journal Of Dermatological Treatment 1999;1:S9-S13.
340. Lambert J, Trompke C. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice. Dermatology 2002;204(4):321-324 (Pubitemid 34665161)
341. Langner A, Ashton P, Van De Kerkhof PC, Verjans H. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. British Journal of Dermatology 1996;135(3):385-389 (Pubitemid 26297832)
342. Lebwohl M, Siskin SB, Epinette WW, Breneman D, Funicella T, Kalb RE, et al. A Multicenter Trial of Calcipotriene Ointment and Halobetasol Ointment Compared with Either Agent Alone for the Treatment of Psoriasis. Journal of the American Academy of Dermatology 1996;35:268-269 (Pubitemid 26260260)
343. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives [comment]. American Journal of Gastroenterology 1990;85(8):962-963 (Pubitemid 20235791)
344. Lee JY, Maibach HI. Corticosteroid skin atrophogenicity: assessment methods. Skin Research & Technology 1998;4(4):161-166
345. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. American Journal of Clinical Dermatology 2006;7(4):231-236 (Pubitemid 44231918)
346. Leu RE. Economic Evaluation of New Drug Therapies in Terms of Improved Life Quality. Social Science & Medicine 1985;21(10):1153-1161
347. Lomholt G. In: GL editor(s). Psoriasis, prevalence, spontaneous course and genetics. Published Ph.D Thesis. Copenhagen: G.E.C. Gad, 1963:31-33
348. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. British Journal of Dermatology. 1999;141(6):1067-1075 (Pubitemid 30046197)
349. Marchetti ALKAP. A Pharmacoeconomic Analysis of Topical Therapies for Patients with Mild-to-Moderate Stable Plaque Psoriasis: A Us Study. Clinical Therapeutics 1998;20(4):851-869
350. Mason JM, Mason AR, Cork MJ. Topical Treatments for Psoriasis in Primary Care. Unpublished data.
351. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. British Journal Of Dermatology 2002;146(3):351-364 (Pubitemid 34603806)
352. Mason J, Mason A, Cork M. Topical preparations for the treatment of psoriasis in primary care: a systematic review. University of York (OP41). York: University of York, 2002.
353. Matthews D, Fry L, Powles A, Weber J, McCarthy M, Fisher E, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nature Genetics 1996;14(2):231-233 (Pubitemid 26338812)
354. McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. British Journal of Dermatology 2003;149(2):323-331 (Pubitemid 37100259)
355. Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. Journal of Investigative Dermatology 1998;110(3):301-302
356. Miyachi Y, Ohkawara A, Ohkido M, Harada S, Tamaki K, Nakagawa H, et al. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. European Journal of Dermatology 2002;12(5):463-468 (Pubitemid 35205136)
357. Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. Acta Dermato-Venereologica 1993;73(4):300-304 (Pubitemid 23282979)
358. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Human Molecular Genetics 1997;6(8):1349-1356 (Pubitemid 27351077)
359. NHS Centre for Reviews & Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD guidelines for those Carrying Out or Commissioning Reviews. CRD Report Number 4 (2nd edition). 2nd. York: CRD, 2001.
360. Oh PI, Gupta AK, Einarson TR, Maerov P, Shear NH. Calcipotriol in the Treatment of Psoriasis of Limited Severity: Pharmacoeconomic Evaluation. Journal of Cutaneous Medicine & Surgery 1997;2(1):7-15. (Pubitemid 28266377)
361. Ortonne JP. Psoriasis: evaluation of quality of life. Annales de Dermatologie et de Venereologie 2000;127(Suppl. 2):2s19-2s22.
362. Osborne JE, Hutchinson PE. The importance of accurate dosage of topical agents: a method of estimating involved area and application to calcipotriol treatment failures. Journal of the European Academy of Dermatology & Venereology 2002;16(4):367-373
363. Owen OG. Healthy returns come from costly drug - prescribing an expensive drug may be the most cost-effective way to treat patients. Healthcare Management 1993;January:52-53
364. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2000, issue 2:CD001976.
365. Park YK, Lee JH, Chung WG. Allergic contact dermatitis from calcipotriol. Acta Dermato-Venereologica 2002;82(1):71-72
366. Parodi A, Guarrera M, Volonte MV. Medicated Tape Versus Cream Formulation - a Major Saving of Fluocinolone Acetonide. Journal Of Dermatological Treatment 1991;1(6):305-306
367. Poyner T, Hughes IW, Dass BK, Adnitt PI. Long-Term Treatment of Chronic Plaque Psoriasis with Calcipotriol. Journal Of Dermatological Treatment 1993;4(4):173-177 (Pubitemid 24031293)
368. Poyner TF, Wall ARJ, Adnitt PI, Menday AP. Economic Impact of Psoriasis Treatment on the Patient and on the National Health Service. Journal Of Dermatological Treatment 1999;10(1):25-29 (Pubitemid 29149962)
369. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. Journal of the European Academy of Dermatology & Venereology 2000;14(3):153-158
370. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PC, et al. Long-Term Use of Topical Calcipotriol in Chronic Plaque Psoriasis. Dermatology 1994;189(3):260-264 [PUBMED: 7949479] (Pubitemid 24249641)
371. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. Journal of the American Academy of Dermatology 1999;41(4):581-583 (Pubitemid 29480408)
372. Richards HL, Fortune DG, Main CJ, Griffiths CE. Stigmatization and psoriasis. British Journal of Dermatology 2003;149(1):209-211
373. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. Journal of the European Academy of Dermatology & Venereology 2006;20(4):370-379
374. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. New England Journal of Medicine 1972;287(15):738-740
375. Salvarani C, Lo Scocco G, Macchioni P, Cremonesi T, Rossi F, Mantovani W, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. Journal of Rheumatology 1995;22(8):1499-1503
376. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?. British Journal of Dermatology 2003;148(6):1153-1160 (Pubitemid 36819214)
377. Schwicker D, Dinkel R, Antunes HC. A Cost-Comparison Study: Ulobetasol Versus Clobetasol in Severe Localized Psoriasis. Journal Of Dermatological Treatment 1992;2(4):127-131
378. Senter TP. Topical fluocinonide and tachyphylaxis letter. Archives of Dermatology 1983;119(5):363-364
379. Simons RD. Additional studies on psoriasis in the tropics and in the starvation camps. Journal of Investigative Dermatology 1949;12:285-294
380. Singh S, Reddy DC, Pandey SS. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. Journal of the American Academy of Dermatology 2000;43(1 Pt 1):61-65 (Pubitemid 30439714)
381. Sorensen M, Norregaard J. Pharmacoeconomic evaluation of a new two compound ointment (Daivobet (R)) and calcipotriol (Daivonex (R)) in the treatment of psoriasis vulgaris in Sweden. Value Health 2002;5(6):554-555
382. Staberg B, Roed-Petersen J, Menne T. Efficacy of topical treatment in psoriasis with Mc903, a new vitamin D analogue. Acta Dermato Venereologica 1989;69(2):147-150 (Pubitemid 19057355)
383. Stern RS. The Benefits, Costs and Risks of Topical Tar Preparations in the Treatment of Psoriasis: Considerations of Cost Effectiveness. [Review] [20 Refs]. Annals Of The Academy Of Medicine, Singapore 1988;17(4):473-476
384. Stern RS. Epidemiology of psoriasis. Dermatologic Clinics 1995;13(4):717-722
385. Stern RS. Psoriasis. Lancet 1997;350(9074):349-353
386. Stevanovic DV, Wilson L, Sparkes CG. A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate. British Journal of Dermatology 1977;96(1):67-70. (Pubitemid 8072501)
387. Svejgaard A, Nielsen LS, Svejgaard E, Nielsen FK, Hjortshoj A, Zachariae H. HL-A in psoriasis vulgaris and in pustular psoriasis - population and family studies. British Journal of Dermatology 1974;91(2):145-153
388. Szeimies RM. Psoriasis: Patient-oriented treatment improves compliance. [German]. Haut 2004;15(5):221-223. (Pubitemid 39310864)
389. Tagami H. Triggering factors. Clinics in Dermatology 1997;15(5):677-685
390. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis & Rheumatism 2006; Vol.54, issue 8:2665-2673 (Pubitemid 44205029)
391. Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW, et al. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Human Molecular Genetics 1999;8(6):1135-1140 (Pubitemid 29250903)
392. Tazi-Ahnini R, di Giovine FS, Cox A, Keohane SG, Cork MJ. Corneodesmosin (MHC S) gene in guttate psoriasis. Lancet 1999;354(9178):597. (Pubitemid 29381391)
393. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264(5162):1141-1145 (Pubitemid 24210675)
394. Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003;207(2):166-172 (Pubitemid 37034346)
395. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Human Molecular Genetics 1997;6(5):813-820 (Pubitemid 27199077)
396. Uhoda I, Quatresooz P, Hermanns-Le T, Pierard-Franchimont C, Arrese JE, Pierard GE. Histometric assessment of psoriatic plaques treated by vitamin D3 derivatives. Dermatology 2003;206(4):366-369 (Pubitemid 36677032)
397. Unna PG. Cignolin als Heilmittel der Psoriasis. Dermatologische Wochenschrift 1916;62:116-137
398. van de Kerkhof PCM, van Harten J, Verjans H. A Long-Term Assessment of the Safety and Tolerability of Calcitriol Ointment in the Treatment of Chronic Plaque Psoriasis. Journal Of Dermatological Treatment 1996;1:S11-S14. (Pubitemid 26288476)
399. van de Kerkhof PC. Combinations and comparisons. Clinics in Dermatology 1997;15(5):831-834
400. van de Kerkhof PCM, van der Vleuten C, Gerritsen M, Glade C, Luger T, Werfel T, et al. Long-Term Efficacy and Safety of Once Daily Treatment of Chronic Plaque Psoriasis with Tacalcitol Ointment. European Journal of Dermatology 1997;7(6):421-425 (Pubitemid 27407975)
401. van de Kerkhof PCM. An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacology & Applied Skin Physiology 1998;11(1):2-10. (Pubitemid 28266285)
402. van de Kerkhof PCM, Steegers Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197(1):31-36 (Pubitemid 28327834)
403. van de Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200(4):292-298
404. van de Kerkhof PCM, Franssen M, de La Brassine M, Kuipers M. Calcipotriol cream in the morning and ointment in the evening: a novel regimen to improve compliance. J. Dermatol. Treat. 2001;12(2):75-79 (Pubitemid 33009885)
405. van de Kerkhof PCM, Berth-Jones J, Griffiths CE, Harrison PV, Honigsmann H, Marks R, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. British Journal of Dermatology 2002;146(3):414-422 (Pubitemid 34603813)
406. Van de Kerkhof PCM, Barker J, Griffiths CEM, Kragballe K, Mason J, Menter A, et al. Psoriasis: Consensus on topical therapies. Journal of the European Academy of Dermatology and Venereology 2008;Vol. 22, issue 7:859-870
407. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. British Journal of Dermatology 2004;151(3):663-668
408. Vazquez-Lopez F, Marghoob AA. Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis. Journal of the American Academy of Dermatology 2004;51(5):811-813 (Pubitemid 39516902)
409. Velema M, Hooft L, Lebwohl M, Spuls PI. Interventions for nail psoriasis (Protocol). Cochrane Database of Systematic Reviews 2009, issue 1:Art. No.: CD007633. DOI: 10.1002/14651858.CD007633.
410. Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Experimental Dermatology 2004;13(2):106-112 (Pubitemid 38247869)
411. Watts J. Helping people to remain in control of their psoriasis. Community Nurse 1998;4(7):19-21.
412. Willan R. On cutaneous diseases. London: Johnson, 1808.
413. Wu T, Jin X, Zhang M, Wei J. Traditional Chinese herbs for psoriasis (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 3. Cochrane Database of Systematic Reviews 2005, issue 3:Art. No.: CD005412. DOI: 10.1002/14651858.CD005412.
414. Yui Yip S. The prevalence of psoriasis in the Mongoloid race. Journal of the American Academy of Dermatology 1984;10(6):965-968
415. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life in 6497 Nordic patients with psoriasis. British Journal of Dermatology 2002;146(6):1006-1016 (Pubitemid 34779481)
416. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Archives of Dermatology 2004;140(4):408-414 (Pubitemid 38469243)
417. Zanolli MD, Wikle JS. Joint complaints in psoriasis patients. International Journal of Dermatology 1992;31(7):488-491
418. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, et al. Assessing the Preferences of Patients with Psoriasis: A Quantitative, Utility Approach. Archives of Dermatology 1995;131(5):561-568